Dartmouth health policy director suspended

Following a complaint about workplace conduct, Elliott Fisher, director of the Dartmouth Institute for Health Policy and Clinical Practice (TDI), has been placed on administrative leave and barred from college property. An investigation is currently underway as well as a search for an interim director.

Fisher has served as TDI director since 2013 and is an international leader in the field of health policy, according to The Dartmouth, the daily student newspaper of Dartmouth College. Fisher helped coin the term "accountable care organizations (ACOs)," which have grown in presence significantly since they were included as a healthcare model under the Affordable Care Act. Fisher is also a professor of family and community medicine at the Geisel School of Medicine.

Adam Keller, TDI’s chief of strategy and operations, was also placed on leave following the complaint. He has been associated with the institute for more than 20 years, serving as administrator, research director, instructor, faculty colleague and advisor. He previously served as executive vice president of finance and administration and vice president for health affairs at Dartmouth, according to the student newspaper.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.